Aleor Dermaceuticals Limited - Due diligence report

A 360° intelligence report on Aleor Dermaceuticals: trust score, financial health, credit view, compliance, directors, growth and distress s…

2016-05-23 Vadodara, Gujarat Amalgamated Unlisted Active Compliant
Share
Connect MCP
AD Aleor Dermaceuticals Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Aleor Dermaceuticals — 360° Intelligence Report

Generated from MCA filings & public records
49/100
Trust Score
Caution Indicated

Aleor Dermaceuticals is assessed as Caution Indicated with a Trust Score of 49/100. Aleor Dermaceuticals is a public limited indian non-government company incorporated in 2016, operating in the Pharma sector. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and high financial risk profile.

Report generated on 14 Aug 2026 from the latest processed filings. Aleor Dermaceuticals Limited snapshot & full profile →

Financial Health › Weak
Overall Assessment CautionWeakNeutralGoodStrong Neutral
Compliance › Weak

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreCaution Indicated
49/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
30/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
30/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
60/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
20/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 50/100 Moderate
  • Negative operating earnings - debt service depends on external support.
  • No open charges - unencumbered balance sheet.
  • Working-capital cover adequate.

Charges position: 0 open (-) · 1 satisfied (300.00 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Others1 48.0 cr
Compliance Score: 30/100 Caution Indicated
  • Company status is "Amalgamated" - not Active.
  • Last balance sheet is for Mar 2021 - filings overdue.
  • 2 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
MITANSHU SATISHBHAI SHAH 01234567 Director 01/04/2018 6 yrs Approved
DHANANJAY MADHUKAR WYAWAHARE 01234567 Director 01/04/2018 6 yrs Approved
RAJKUMAR SHREERAM BAHETI 01234567 Director 01/04/2018 6 yrs Approved
KEVALKUMAR B THAKKAR 01234567 Director 01/04/2018 6 yrs Approved
JESAL NIRANJAN SHAH 01234567 Director 01/04/2018 6 yrs Approved
  • 5 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2021)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2021 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Alembic Pharmaceuticals
Subsidiaries
-
Group entities
-
Capital events
38 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Alembic Pharmaceuticals Holding Company 74.00%

Key managerial personnel: DHANANJAY MADHUKAR WYAWAHARE (CEO)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 60 · Distress 20
Growth signals & trust indicators
Latest year revenue grew 38%.
Operating for 10+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Losses deepening year-on-year.
Negative net worth.
Statutory filings appear overdue.
Adverse company status: Amalgamated.
Compliance score is weak (30/100).
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence33/100
Caution indicated
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 4 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment39/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance gaps should be priced into terms.
Investor view47/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
02 Sep 2022
Charge satisfied
Others
28 Mar 2022
Director ceased
MOHAN SIVARAMAN MAILTUR
16 Mar 2022
Securities allotted
500 Debentures - 5.00 cr raised
08 Feb 2022
Securities allotted
700 Debentures - 7.00 cr raised
05 Oct 2021
Securities allotted
2500 Debentures - 25.00 cr raised
20 Jul 2021
Last AGM held
Annual general meeting
22 Jun 2021
Securities allotted
2500 Debentures - 25.00 cr raised
07 Apr 2021
Securities allotted
3000 Debentures - 30.00 cr raised
31 Mar 2021
Latest balance sheet
Filed with ROC
16 Feb 2021
Securities allotted
2000 Debentures - 20.00 cr raised
07 Dec 2020
Securities allotted
3000 Debentures - 30.00 cr raised
20 Oct 2020
Director appointed
DHANANJAY MADHUKAR WYAWAHARE (CEO)
Director ceased
HIREN DASHARATHBHAI PATEL
Director ceased
RAHUL GAWANDE SUDHAKAR
12 Oct 2020
Securities allotted
3000 Debentures - 30.00 cr raised
10

Key Observations

Auto-generated from the data above
5 active director(s) / partner(s); board looks stable and experienced.
2 active GST registration(s) indicate ongoing business operations.
All 1 registered charge(s) stand satisfied - past borrowings repaid.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2021 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 38 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Septodont Healthcare India Private Limited U24239MH1999PTC250164 Navi Mumbai, Maharashtra, India
Sri Chementor Private Limited U24296PY2008PTC002143 Puducherry, Pondicherry, India
Sm Pharmaceuticals U24230KA2018PTC119625 Bangalore North, Karnataka, India
Thaikkattu Mooss Vaidyaratnam Oushadhasala Private Limited U24233KL1987PTC004694 Trichur, Kerala, India
Jash Pharma Private Limited U24239MH2005PTC158290 Mumbai, Maharashtra, India
Aaa Salt And Chemicals Private Limited U14299GJ2018PTC100427 Vadodara, Gujarat, India
Fantasy Drugs Private Limited U00893BR1998PTC008367 Patna, Bihar, India
Agrilife U24219TG1993PLC016199 Medak, Telangana, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Aleor Dermaceuticals before audits and certifications: compliance score 30/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Aleor Dermaceuticals: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Enhanced diligence advised. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 60/100, margin trends, ownership structure and peer set for Aleor Dermaceuticals - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Caution indicated. Trust score 49/100, distress signals and MSME payment-delay disclosures - know whether Aleor Dermaceuticals pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Aleor Dermaceuticals - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Aleor Dermaceuticals an active company?

Aleor Dermaceuticals has MCA status “Amalgamated” with a compliance score of 30/100 (Caution Indicated).

Is Aleor Dermaceuticals financially healthy?

Aleor Dermaceuticals has a Financial Health Score of 30/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Aleor Dermaceuticals?

Its overall Trust Score is 49/100 (Caution Indicated). Vendor verdict: Caution indicated. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Aleor Dermaceuticals?

The ultimate holding entity is Alembic Pharmaceuticals. 5 active director(s) are on record.

Does Aleor Dermaceuticals have loans or charges against its assets?

No open charges - all 1 registered charge(s) stand satisfied, indicating past borrowings were repaid.

Is Aleor Dermaceuticals up to date with its ROC filings?

Last balance sheet is for Mar 2021 - filings overdue. Overall compliance score: 30/100 (Caution Indicated).

Is it risky to lend to Aleor Dermaceuticals?

Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Enhanced diligence advised.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.